Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00310843 · ClinicalTrials.gov registry record
Case-Control Viramune (Nevirapine) Toxicogenomics Study
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 889
- Enrollment target
NCT00310843: Completed study, sponsored by Boehringer Ingelheim.
NCT00310843 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 889 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00310843 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 889 participants
- Enrollment target
Study Summary
Attempt to identify genetic polymorphisms in interrogated pathways which may be associated with symptomatic hepatotoxicity or severe cutaneous toxicity observed in case patients within the first 8 weeks of nevirapine therapy.
Interventions
- DRUG Nevirapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 889 participants |
| Start Date | 2006-02 |
What the finished NCT00310843 record still lists
NCT00310843 is an observational study that tracks outcomes without assigning an intervention. The registered 889 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Nevirapine is the first listed.
NCT00310843 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00310843 about?
NCT00310843 is a clinical study titled "Case-Control Viramune (Nevirapine) Toxicogenomics Study". Attempt to identify genetic polymorphisms in interrogated pathways which may be associated with symptomatic hepatotoxicity or severe cutaneous toxicity observed in case patients within the first 8 weeks of nevirapine therapy.
What is the current status of trial NCT00310843?
This trial is currently completed. The enrollment target is 889 participants. The study started on 2006-02.
What interventions are being tested in trial NCT00310843?
The interventions under investigation include: Nevirapine (DRUG).
Who is sponsoring clinical trial NCT00310843?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03564340 · 890 participants · Phase 1
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- NCT05855200 · 892 participants · Phase 3
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
- NCT04862663 · 895 participants · Phase 3
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
- NCT07196748 · 882 participants · Phase 3
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia